OncoMatch/Clinical Trials/NCT06801236
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Is NCT06801236 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ACE-232 tablets for prostate cancer (adenocarcinoma).
Treatment: ACE-232 tablets — This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: novel hormonal agent — mHSPC or mCRPC
post at least 1 line of NHA
Must have received: taxane — mHSPC or mCRPC
post at least 1 line of ... taxane-based chemo
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate organ function and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California San Diego, Moores Cancer Center · La Jolla, California
- Moffitt Cancer Center, Tampa · Tampa, Florida
- University of Maryland, Greenebaum Comprehensive Cancer Center · Baltimore, Maryland
- Harvard Medical School-Massachusetts General Hospital · Boston, Massachusetts
- M Health Fairview Clinics and Surgery Center · Minneapolis, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify